Henry Gosebruch, pictured here during his time at Neumora, is replacing Paul Stoffels as CEO of Galapagos. Just a few months after announcing a plan to separate its drug and cell therapy businesses ...
Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its innovative medicines and cell therapy businesses, which will result in the loss of around 300 jobs or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results